In a presentation sent to UK hospitality customers and described by the Guardian from a Reuters report, the brewer said GLP-1 drugs such as Wegovy and Ozempic could reduce the desire to drink alcohol, leading to “fullness and fewer serves” and making the traditional multi-pint session less common. Its advice was practical: push half-pints, expand low- and zero-alcohol options, and pair drinks with small plates.
That is a notable message from one of the world’s largest brewers because it treats a prescription trend as a pub trade problem. Heineken is not saying customers vanish. It is saying they may become less lucrative: smaller serves, lower-alcohol drinks, more selective orders.
The company said it is monitoring “changes in consumption behaviour” among GLP-1 users and framed those habits as part of a broader shift toward moderation, choice and more intentional consumption. That is also where the claim needs to stay. Heineken is making a commercial assessment for its customers, not settling a scientific argument.
Others in the drinks business are less convinced. The Guardian reported that Diageo has told investors any impact from mainstream GLP-1 use should be manageable, while Carlsberg told Reuters its data did not support the view that weight-loss drugs were affecting beer consumption trends. Heineken, for its part, pointed to surveys from Circana, NIQ and KAM suggesting GLP-1 users are drinking less.
The trade does not appear to agree on the scale of the threat. It agrees enough to game out the menu.
Heineken’s own numbers show why the warning matters. British pubs, bars and restaurants took in almost £14bn from beer sales in the year to February, while less than £300m came from no- and low-alcohol products. A move toward shorter orders and different choices would not have to be universal to be felt across that market.
For pubs, this is not really a story about prohibition or sudden sobriety. It is about the possibility that a customer still wants the pub, just not the second or third pint that used to make the economics easy.
Alex de Valletta
Marcus Azzopardi
Ryan C